Pedro Mendez

A data-driven leader with expertise in drug discovery, target identification and validation, molecular diagnostics, precision medicine, RNA therapeutics, and genome/epigenome
editing. Product owner and self-starter mindset. Provide Scientific, technical, and operational guidance/oversight for product development. Proficient in biomarkers discovery, development of cutting-edge technology, products, assays development ( bulk and single-cell multi-omics), mRNA, siRNA, gene editing) across different fields. 
Proficient in Python and R, analyzing and extracting Biological insights from complex datasets (scRNA-seq / scDNA-seq / WES, RNA-seq, epigenomics assays). Extensive expertise in sample preparation, chemical biology, enzymology, and molecular biology. 
Utilize excellent interpersonal, communication, and project management skills to develop strategies and improve processes, driving value that aligns with company goals. 

Moonwalk Bio: 

Director R&D, : March 2023 - Present

Synthego Corporation: 

Associate Director, Analytical R&D (Sep 2022 - March 2023)

Lead Scientist, Translational Biology (Sep 2021 - Sep 2022)

Sr. Scientist, Pre-clinical (May 2020 - Sep 2021) 

Mission Bio: 

Sr, Scientist, Research, Applications and Collaborations (April 2019 - May 2020)

Scientist, Research, Applications and Collaborations (Sep 2017 - April 2019)

USCF, Applied Genomics Laboratory (Thoracic Oncology):

Full Specialist III (Sep 2013 - Sep 2017)

CureSeq Inc. 

R&D Lead Scientist (April 2014 - March 2017)

Translational Oncology Laboratory (IGTP, Spain)

Research Scientist III (Mar 1998 - Aug 2013)

BS, Biological Sciences, Central University of Barcelona. 

Anatomic Pathology Technician, La Guineueta, Barcelona.